As speculation mounts over pricing for remdesivir, a Gilead Sciences (GILD) executive suggested the experimental medicine will likely sell for much less than the nearly $30,000 it was recently valued at in a cost-effectiveness model, according to a Wall Street analyst.

At the same time, the drug maker believes remdesivir has the potential to become a “multi-year commercial opportunity,” rather than provide just a surge in sales for a year or two, Leerink analyst Geoffrey Porges wrote in an investor note sent on Monday that summarized a conversation he had with Gilead chief financial officer Andrew Dickinson.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy